08 March 2002
Patient acceptance and reliability of new Humulin/Humalog 3.0 ml pre-filled insulin pen in ten Croatian diabetes centres.
John Wyatt, Nadia Mincheva, Ante Petrusic, Ante Ivandic, Tomislav Cabrijan, Eduard Galic, Mate Sucic, Zvonko Milicevic, James MaloneMed Sci Monit 2002; 8(3): PI21-26 :: ID: 420916
Abstract
BACKGROUND: The objective of this study was to assess feature preferences,patient acceptance, reliability, and safety of the new Lilly Humulin/Humalog 3.0 ml prefilled insulinpen in a clinical setting. MATERIAL/METHODS: A total of 330 patients in Croatia with type 1 or type 2diabetes mellitus who required at least one injection of insulin per day were treated with Humulin 30/70or Humalog for 4 to 6 weeks using the new prefilled pen. Questionnaires concerning various aspects ofthe pen performance were administered at endpoint. RESULTS: The features of the Lilly 3.0 ml pen deviceranked most highly by patients (% of excellent or good ratings) were cartridge visibility (93%), attaching/replacingneedles (93%), ease of dose correction (92%), checking insulin flow (90%) and dialling of insulin dose(89%). Features of the pen device rated most highly by patients in comparison with the delivery systemsused before the study and the percentage of patients rating those features as much better or better wereease of dose correction (74%), cartridge visibility (67%), audible dialing clicks (55%) and size of dosenumbers (52%). Most respondents (78%) preferred single-unit versus two-unit dosage increments. The majorityof patients rated the new prefilled pen as being more convenient and easier to use, and indicated thatit represented a significant or modest an improvement over their previous insulin injection method. CONCLUSIONS:The results of this study indicate that the new Lilly 3.0 ml prefilled pen is acceptable for patientswho were previously using either reusable devices or the traditional syringe and vial.
Keywords: Adolescent, Aged, 80 and over, Croatia, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Equipment Design, Injections, Insulin, Patient Compliance, Patient Education, Patient Satisfaction, Questionnaires, Reproducibility of Results, Syringes
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952